Prolactinomas and menopause: any changes in management?
Author:
- 4 November 2019
- journal article
- review article
- Published by Springer Nature in Pituitary
- Vol. 23 (1) , 58-64
Abstract
Treatment goals in prolactinomas are to correct hypogonadism, restore fertility and control tumor mass in case of macroadenomas. According to current guidelines, medical treatment of asymptomatic postmenopausal women is not indicated. The purpose of this study was to review the current literature pertaining to biological behavior of prolactinomas during menopause, likelihood of successful dopamine agonist withdrawal during this period and possible prolactin-mediated increased morbidity that could modify current management.Keywords
This publication has 60 references indexed in Scilit:
- Prevalence of pituitary adenomas: a community‐based, cross‐sectional study in Banbury (Oxfordshire, UK)Clinical Endocrinology, 2010
- The risk for breast cancer is not evidently increased in women with hyperprolactinemiaPituitary, 2009
- Prolactin Levels and the Risk of Future Coronary Artery Disease in Apparently Healthy Men and WomenCirculation: Cardiovascular Genetics, 2009
- Evidence for direct effects of prolactin on human osteoblasts: Inhibition of cell growth and mineralizationJournal of Cellular Biochemistry, 2009
- Subclinical adenomas in postmortem pituitaries: classification and correlations to clinical dataEuropean Journal of Endocrinology, 2006
- The prevalence of pituitary adenomasCancer, 2004
- Long‐term follow‐up of patients with hyperprolactinaemiaClinical Endocrinology, 1996
- Relationship of Blood Prolactin Levels and the Risk of Subsequent Breast CancerInternational Journal of Epidemiology, 1992
- The Pituitary Gland in Pregnancy: A Clinicopathologic and Immunohistochemical Study of 69 CasesMayo Clinic Proceedings, 1990
- HYPERPROLACTINAEMIA IN MALES WITH AND WITHOUT PITUITARY MACROADENOMASThe Lancet, 1982